Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 3/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106944 | 1.00 | MTOR (0.44) | MTORPIK3CDPIK3CAKCNH2ATR | |
| SCHEMBL24955727 | 1.00 | MTOR (0.44) | MTORPIK3CDPIK3CAKCNH2ATR | |
| SCHEMBL31106953 | 0.93 | MTOR (0.43) | MTORPIK3CDPIK3CAATRATRIP | |
| SCHEMBL24955725 | 0.93 | MTOR (0.43) | MTORPIK3CDPIK3CAATRATRIP | |
| SCHEMBL31106989 | 0.93 | MTOR (0.43) | MTORPIK3CDPIK3CAATRATRIP | |
| SCHEMBL24955629 | 0.88 | PIK3CA (0.39) | MTORPIK3CADGAT1 | |
| SCHEMBL30202168 | 0.86 | MTOR (0.49) | MTORPIK3CDPIK3CAKCNH2ATR | |
| SCHEMBL30202248 | 0.86 | MTOR (0.49) | MTORPIK3CDPIK3CAKCNH2ATR | |
| SCHEMBL24955726 | 0.85 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL31106972 | 0.85 | DGAT1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | MTOR 777/4885PIK3CD 1550/4885PIK3CA 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.